arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

EDAP TMS SA

FOCL
$6.22 ▲ +0.09 (+1.55%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
15 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

EDAP TMS SA faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $233.1M
Dividend Yield
Revenue Growth 24.8%
Op. Margin -41.4%
ROIC -25.7%
FCF / Share $-0.08
Trailing P/E
Price / Book 23.1x
FCF Yield
Debt / Equity 2.41
info Valuation on last close. End-of-day price, Aug 7, 2026.

15-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$17.81M
↑ +24.8%
Net Income Profit after all expenses
$-9.08M
↓ -22.0%
Operating Margin Operating profit as % of sales
-41.4%
↑ +6.5% 7th
FCF / Share Free cash flow per share
$-0.08
↑ +44.5%
Long-Term Debt Long-term obligations
$19.06M
↑ +5.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
7
Returns
5
Financial Health
21
Cash Quality
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 15 quarters